<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692705</url>
  </required_header>
  <id_info>
    <org_study_id>D0180C00018</org_study_id>
    <secondary_id>Eudract No. 2007-004842-33</secondary_id>
    <nct_id>NCT00692705</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid</brief_title>
  <acronym>PET</acronym>
  <official_title>Open Label Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Healthy Volunteers and Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is carried out in order to investigate if [11C]AZD2995, compared to [11C]AZD2184,
      is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human
      brain. In the study the two PET ligands will be examined in both healthy volunteers and
      patients with Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron emission tomography using the radioligand (11C)AZD2995 or (11C)AZD2184</measure>
    <time_frame>Radioligand (11C)AZD2995.1-2 PET examinations for AD patients and 1 PET examination for healthy volunteers. - Radioligand (11C) AZD2184.One PET for AD patients respective healthy volunteers.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety and tolerability of [11C]AZD2995, [11C]AZD2184 and the study procedures, by assessment of adverse events, vital signs and laboratory variables.</measure>
    <time_frame>3-4 visits with tests for the AD patients. 3 visits with tests for the healthy volunteers. All tests are not done at every visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Alzheimer´s Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Alzheimer's Disease (AD) patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radioligand (11C)AZD2995</intervention_name>
    <description>Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radioligand (11C)AZD2184</intervention_name>
    <description>Single dose of i.v solution. Once for AD patients respective healthy volunteers.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alzheimer´s Disease patients - 50-85 years- mild to moderate AD, clinical progression
             of AD over 12 months.

          -  Healthy male volunteers: - Age 20-50 years, Body Mass Index: 18-30 kg/m2.

          -  Clinically normal physical findings including normal blood pressure and pulse rate.

        Exclusion Criteria:

          -  Alzheimer´s Disease patients:

          -  significant cerebrovascular disease or depression, central nervous system infarct or
             infection or lesions

          -  clinically significant illness within 2 weeks before the study start.

          -  administration of any investigational product with effect on brain beta amyloid levels
             within 3 months prior to study and/or participation in a PET investigation other than
             study D0180C00011 as part of a scientific study during the past 12 months,.

          -  Healthy volunteers; - clinically significant illness within 2 weeks before the study
             start, history of psychiatric or somatic disease/condition that may interfere.- first
             degree relative with dementia. Obvious deterioration of memory functions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria E Jönhagen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingemar Bylesjö</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emma Gyllenpalm</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>January 22, 2009</last_update_submitted>
  <last_update_submitted_qc>January 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Märta Segerdahl, Medical Science Director</name_title>
    <organization>AstraZeneca, Research and Development, Sweden</organization>
  </responsible_party>
  <keyword>Alzheimer´s Disease</keyword>
  <keyword>amyloid deposits</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

